Fulcrum Therapeutics Inc (NASDAQ:FULC)’s traded shares stood at 0.7 million during the last session, with the company’s beta value hitting 2.11. At the close of trading, the stock’s price was $3.99, to imply an increase of 4.18% or $0.16 in intraday trading. The FULC share’s 52-week high remains $13.70, putting it -243.36% down since that peak but still an impressive 28.32% since price per share fell to its 52-week low of $2.86. The company has a valuation of $215.22M, with an average of 0.79 million shares in intraday trading volume over the past 10 days and average of 1.68 million shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for Fulcrum Therapeutics Inc (FULC), translating to a mean rating of 2.62. Of 13 analyst(s) looking at the stock, 0 analyst(s) give FULC a Sell rating. 0 of those analysts rate the stock as Overweight while 4 advise Hold as 9 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.29.

Fulcrum Therapeutics Inc (NASDAQ:FULC) trade information

After registering a 4.18% upside in the last session, Fulcrum Therapeutics Inc (FULC) has traded red over the past five days. The 5-day price performance for the stock is 3.64%, and 16.33% over 30 days. With these gigs, the year-to-date price performance is -40.89%. Short interest in Fulcrum Therapeutics Inc (NASDAQ:FULC) saw shorts transact 4.97 million shares and set a 7.67 days time to cover.

The extremes give us $2 and $4 for target low and target high price respectively. As such, FULC has been trading -0.25% off suggested target high and 49.87% from its likely low.

Fulcrum Therapeutics Inc (FULC) estimates and forecasts

Looking at statistics comparing Fulcrum Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Fulcrum Therapeutics Inc (FULC) shares are -51.87% down over the last 6 months, with its year-to-date growth rate higher than industry average at 89.94% against 17.50%. The rating firms project that company’s revenue will grow 2,764.67% compared to the previous financial year.

An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 1.09% for the past 5-year period. While 2024 is set for a 90.17% return in earnings, projections for the next 5 years are at 16.40% annually.

FULC Dividends

Fulcrum Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Fulcrum Therapeutics Inc (NASDAQ:FULC)’s Major holders

Fulcrum Therapeutics Inc insiders hold 1.62% of total outstanding shares, with institutional holders owning 89.70% of the shares at 91.17% float percentage. In total, 89.70% institutions holds shares in the company, led by RA CAPITAL MANAGEMENT, L.P. As of 2024-06-30, the company held over 11.61 million shares (or 18.7302% of shares), all amounting to roughly $71.98 million.

The next major institution holding the largest number of shares is RTW INVESTMENTS, LP with 5.85 million shares, or about 9.4314% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $36.24 million.

We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Fulcrum Therapeutics Inc (FULC) shares. Going by data provided on Sep 30, 2024, Vanguard Total Stock Market Index Fund holds roughly 1.85 shares. This is just over 3.43% of the total shares, with a market valuation of $7.39 million. Data from the same date shows that the other fund manager holds a little less at 1.64, or 3.05% of the shares, all valued at about 6.56 million.